Press release
ADCs CMO & CDMO Market Outlook 2025-2031: Key Drivers, Emerging Technologies, and Strategic Collaborations Unveiled
Antibody-drug Conjugates (ADCs) CMO and CDMO Market SizeThe global market for Antibody-drug Conjugates (ADCs) CMO and CDMO was valued at US$ 3863 million in the year 2024 and is projected to reach a revised size of US$ 12840 million by 2031, growing at a CAGR of 19.0% during the forecast period.
Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-26P18765/Global_Antibody_drug_Conjugates_ADCs_CMO_and_CDMO_Market_Research_Report_2025
North American market for Antibody-drug Conjugates (ADCs) CMO and CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Antibody-drug Conjugates (ADCs) CMO and CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Antibody-drug Conjugates (ADCs) CMO and CDMO in Solid Tumors is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Inquire for Discount: https://reports.valuates.com/request/discount/QYRE-Auto-26P18765/global-antibody-drug-conjugates-adcs-cmo-and-cdmo
The major global companies of Antibody-drug Conjugates (ADCs) CMO and CDMO include Lonza Group, Merck KGaA, WuXi XDC, Abbvie, Piramal Pharma Solutions, Catalent, Sterling Pharma Solutions, Axplora, Aji Bio-Pharma, BSP Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Antibody-drug Conjugates (ADCs) CMO and CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody-drug Conjugates (ADCs) CMO and CDMO.
The Antibody-drug Conjugates (ADCs) CMO and CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Antibody-drug Conjugates (ADCs) CMO and CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
By Type
• Cleavable linkers
• Non-cleavable linkers
By Application
• Solid Tumors
• Hematological Malignanciesncies
Key Companies
Lonza Group, Merck KGaA, WuXi XDC, Abbvie, Piramal Pharma Solutions, Catalent, Sterling Pharma Solutions, Axplora, Aji Bio-Pharma, BSP Pharmaceuticals, Cerbios-Pharma, Goodwin Biotechnology, TOT Biopharm, Huadong Medicine, Innovent Biologics, Shanghai Henlius Biotech
View Full Report: https://reports.valuates.com/market-reports/QYRE-Auto-26P18765/global-antibody-drug-conjugates-adcs-cmo-and-cdmo
Please reach us at sales@valuates.com
Address:
Valuates,
4th Floor,
Balaraj's Arcade,
Whitefield Main road,
Bangalore 560066
Valuates offers an extensive collection of market research reports that helps companies to take intelligent strategical decisions based on current and forecasted Market trends.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release ADCs CMO & CDMO Market Outlook 2025-2031: Key Drivers, Emerging Technologies, and Strategic Collaborations Unveiled here
News-ID: 4043245 • Views: …
More Releases from Valuates Reports
DRAM for Data Centers Market Set to Surge - Key Insights You Must Know
DRAM for Data Centers Market Size
The global market for DRAM for Data Centers was valued at US$ 6200 million in the year 2024 and is projected to reach a revised size of US$ 11030 million by 2031, growing at a CAGR of 7.3% during the forecast period.
Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-19E19172/Global_DRAM_for_Data_Centers_Market_Research_Report_2025
This report studies the DRAM for data centers, mainly incldue DIMM.
DIMM stands for Dual-Inline Memory Modules, which refers to dual in-line…
Data Center Optical Distribution Frames Market Set to Surge - Key Insights You M …
Data Center Optical Distribution Frames Market Size
The global market for Data Center Optical Distribution Frames was valued at US$ 591 million in the year 2024 and is projected to reach a revised size of US$ 801 million by 2031, growing at a CAGR of 4.5% during the forecast period.
Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-3V9328/Global_Data_Center_Optical_Distribution_Frames_Market_Outlook_2022
There are many companies of the global Data Center Optical Distribution Frames market, among which key players are Huawei,…
Data Centre Networking Market Set to Surge - Key Insights You Must Know
Data Centre Networking Market Size
The global Data Centre Networking market was valued at US$ 16180 million in 2023 and is anticipated to reach US$ 26080 million by 2030, witnessing a CAGR of 7.0% during the forecast period 2024-2030.
Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-4J2452/Global_Data_Centre_Networking_Market_Insights_Forecast_to_2028
Data centre is used to house the computer systems and its associated components such as storage systems and telecommunications. Backup power supplies and redundant data stores are included in the…
Data Center Damper Market Set to Surge - Key Insights You Must Know
Data Center Damper Market
The global market for Data Center Damper was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-27P14952/Global_Data_Center_Damper_Market_Insights_Forecast_to_2029
The new DC "data center" models are high-performing airfoil blade type, and offer the lowest AMCA Class 1A leakage rating for energy savings. They also offer a…
More Releases for Conjugates
Global Cancer Antibody Drug Conjugates Market
Global Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030 Report Finding & Inclusions:
• Global Cancer Antibody Drug Conjugates Market: 2020 - 2030
• Global Cancer Antibody Drug Conjugates Market Opportunity > US$ 50 Billion By 2030
• Approved Cancer Antibody Drug Conjugates: 16 Drugs
• Approved Cancer Antibody Drug Conjugates Sales Insights, Patent, Dosage and Price Analysis
• Cancer Antibody Drug Conjugates In Clinical Trials: > 500 Drugs
• Cancer Antibody Drug Conjugates Clinical…
Bispecific Antibody Drug Conjugates Development
The development of bispecific antibody drug conjugates (ADCs) marks a significant advancement in the field of targeted cancer therapy. These innovative molecules combine the specificity of bispecific antibodies with the powerful cytotoxic effects of drug conjugates, creating a new class of therapeutic agents that hold great promise for treating complex and resistant cancers. The process of developing these ADCs involves intricate design, engineering, and testing to ensure their safety, efficacy,…
DLL3 Antibody-Drug Conjugates: Mechanisms and Efficacy
Antibody-drug conjugates (ADCs) represent a revolutionary approach in cancer treatment, combining the targeting capabilities of antibodies with the cytotoxic power of chemotherapy. DLL3 (Delta-Like Ligand 3) has emerged as a promising target for ADCs, particularly in the treatment of small cell lung cancer (SCLC) and other neuroendocrine tumors. This article explores the mechanisms and efficacy of DLL3 ADCs, shedding light on their potential in modern oncology.
Download Report:
https://www.kuickresearch.com/report-dll3-targeted-therapies-dll3-cancer-therapies-dll3-protien-dll3-cancer-drugs-delta-like-ligand-3-dll3-gene-dll3-expression-dll3-amgen-dll3-inhibitor
DLL3 is a…
Radionuclide Drug Conjugates (RDC) Market Minimizing Side Effects, Maximizing Im …
Radionuclide Drug Conjugates (RDCs) Market to Record an Exponential CAGR by 2031 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Radionuclide Drug Conjugates (RDCs) Market Size, Share & Trends Analysis Report By Type (Antibody Radionuclide Conjugates (ARC), Peptide Radionuclide Conjugates (PRC), Small Molecular Radionuclide Conjugates (SMRC)), Disease Indication (Neuroendocrine Tumors, Prostate Cancer, Renal Cell, Carcinoma, Others)- Market Outlook…
Oncology Antibody Drug Conjugates Market Size & Trends
According to a new market research report published by Global Market Estimates, the Global Oncology Antibody Drug Conjugates Market is projected to grow from USD 9.87 billion in 2022 to USD 22.48 billion at a CAGR value of 12.4% from 2022 to 2027.
Pfizer Inc., Astellas Pharma Inc., Gilead Sciences, Inc., GlaxoSmithKline, F. Hoffmann-La Roche AG, Daiichi Sankyo, AstraZeneca, Sanofi, AbbVie, Merck & Co., Byondis, RemeGen, ImmunoGen, Seagen, Rakuten Medical,…
Global Antibody Drug Conjugates Market Insights, Forecast
Antibody Drug Conjugates are highly effective biopharmaceutical medications designed as a targeted therapy for cancer treatment. The preparation process of ADC’s involves great difficulty, inspite of these hurdles recently approved ADC’s have proved their worth for treatment of cancer. Thus, there is a strong pipeline of ADC’s that promises revolutionary changes in area of targeted therapy for cancer treatment. This market is driven by elements such as continuous improvement…